Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$472.35 USD

472.35
432,975

+3.17 (0.68%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 249)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

LabCorp (LH) Strong on Strategic Planning, Competition Rife

LabCorp (LH) grows on strong diagnostics business amid softness in the Covance drug development business.

    DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

    DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.

      Ecolab (ECL) to Divest Equipment Care Segment, Shares Fall

      In August, management at Ecolab (ECL) announced that equipment care business has been witnessing a quiet period, registering just 2% growth on a year-over-year basis in the last quarter.

        Veeva Systems (VEEV) Rides High on Commercial Cloud Platform

        The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Veeva's (VEEV) industry-specific focus lends it a significant leverage.

          Henry Schein Closes Merritt Buyout, Expands in Animal Health

          Henry Schein (HSIC) is consistently trying to expand its Animal Health business.

            CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3

            CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.

              Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders

              Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.

                QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife

                The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.

                  Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business

                  Express Scripts (ESRX) is consistently trying to expand its core PBM business.

                    The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT

                    The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT

                      5 MedTech Stocks for Stellar Returns in Q3

                      Here we take a sneak peek into two burning issues that are likely to impact the quarterly numbers in the MedTech fraternity.

                        4 Top Growth Picks as MedTech Battle Rages On

                        Trump's Obamacare replacement saga has made growth picks great opportunities for investors in MedTech sector.

                          Pacific Biosciences, Bluebee Team Up for De Novo Sequencing

                          With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.

                            QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite

                            QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.

                              Illumina (ILMN) Strong on Product Launches, Competition Rife

                              Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.

                                Fresenius Medical (FMS) Well Poised on Growth Strategy 2020

                                Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.

                                  Boston Scientific Grows on New Products, Currency Woe Ails

                                  Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.

                                    DaVita Banks on Acquisitions, Escalating Expenses a Concern

                                    DaVita HealthCare Partners' (DVA) focus on acquisitions will boost the company's expansion. However, rising expenses remains headwind.

                                      Hurricane Maria to Hurt Medtronic in Q2, FY18 View Intact

                                      Medtronic (MDT) expects normal manufacturing process in Puerto Rico to resume in full force in the coming weeks with considerable repairing done in the aftermath of Hurricane Maria.

                                        Teleflex (TFX) Hits a 52-Week High on NeoTract Acquisition

                                        NeoTract acquisition is expected to generate mid-single digit constant currency revenue growth for the next several years and enhance Teleflex's (TFX) margins.

                                          Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm

                                          Integra (IART) widens its tissue technology segment with the launch of Revize/Revize-X Collagen Matrix for plastic and reconstructive surgery.

                                            Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?

                                            The market is upbeat about Abbott's (ABT) recent FDA approvals and buyouts.

                                              QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm

                                              QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.

                                                Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval

                                                Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.

                                                  PerkinElmer Hits a 52-Week High: What's Driving the Stock?

                                                  PerkinElmer's (PKI) portfolio has not only boosted the company's organic growth trajectory but has also helped boost market share worldwide. Solid estimate revision trend boosts investor confidence.